Emmanuel Krupka

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Placebo Controlled

Allergic Rhinitis

Top Venues

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Annemie Deiteren, Lieselot Bontinck, Griet Conickx, Marie Vigan, Nele Dervaux, Matthieu Gassiot, Selcuk Bas, Benjamin T Suratt, Heribert Staudinger, Emmanuel Krupka
A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science 17 (6) (2024)
Annemie Deiteren, Lieselot Bontinck, Griet Conickx, Marie Vigan, Nele Dervaux, Matthieu Gassiot, Selcuk Bas, Benjamin T Suratt, Heribert Staudinger, Emmanuel Krupka
A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science 17 (6) (2024)
Annemie Deiteren, Lieselot Bontinck, Griet Conickx, Marie Vigan, Nele Dervaux, Matthieu Gassiot, Selcuk Bas, Benjamin T Suratt, Heribert Staudinger, Emmanuel Krupka
A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP/anti-IL-13 NANOBODY® compound, in healthy volunteers. Clinical and translational science 17 (6) (2024)
Agnes Hincelin-Mery, Xavier Nicolas, Cathy Cantalloube, Robert Pomponio, Pascale Lewanczyk, Myriam Benamor, Dimitry Ofengeim, Emmanuel Krupka, Jennifer Hsiao-Nakamoto, Amy Eastenson, Nazem Atassi
Safety, Pharmacokinetics, and Target Engagement of a Brain Penetrant RIPK1 Inhibitor, SAR443820 (DNL788), in Healthy Adult Participants. Clinical and translational science (2023)